Digoxin therapy may reduce the risk for new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease.

A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker bisoprolol (Zebeta) in patients with atrial ...

Evaluation of the drug by Canadian regulatory authorities is under way. Paladin Labs will take over distribution of BTG’s treatment for digoxin toxicity or overdose in Canada. DigiFab™ is currently ...

Digoxin, a cardiac glycoside derived from the foxglove plant, has been a mainstay of treatment in systolic heart failure and in rate control for atrial fibrillation. By inhibiting the cardiac ...

Cyanide binds to the ferric ion on cytochrome oxidase and abruptly halts the electron transport chain and aerobic respiration, producing profound toxic effects. Cyanide also preferentially binds to ...

Digoxin recalled over mislabeling Two lots of Digoxin were mislabeled, leading to a recall. Digoxin is used for the treatment of mild to moderate heart failure in children and adults. The Food and ...

BUFFALO, N.Y. – University at Buffalo researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart ...

University at Buffalo researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin.